Allergy Drug Pipeline and R&D 2009

Emerging Technologies, Companies, Products, Applications, Sales & Market Share, and Worldwide Outlook

Publication Date	June 2009
Publisher	Fuji-Keizai
Product Type	Report
Pages	126
ISBN Number	not applicable
Product Code	FUJ00069

Buy this product or for assistance call +44 20 7060 7474

PDF £990.00$1647 | €1108

PRINT £660.00$1098 | €739

FAX Order above formats by FAX

Summary

This report describes current global research initiatives in the field of allergies. It focuses on the most common allergies, which affect more than 300 million persons worldwide: seasonal and perennial allergic rhinitis and food allergies.

Sales estimates from 2008 to 2013 are provided for the leading prescription allergy drugs and vaccines, as well as over-the-counter (OTC) allergy medicines in the U.S., European Union, Japan and rest of world area (defined as South America and the Caribbean, Middle East, Africa, and Asia except Japan). Forecasts include an analysis of the market forces affecting sales in each region, as well as a discussion of patent expirations of leading medications and the effects of generic competition on existing allergy drug sales.

Allergy medications and vaccines under development are discussed, with a comprehensive analysis of technology, stage of development and commercialization potential. This includes new molecular entities and indication expansions of medicines currently approved for other uses. For leading allergy drug candidates, sales estimates from 2009 to 2013 are provided.

Profiles of the 12 leading allergy drug developers offer details of these companies' capabilities, particularly focusing on R&D strength, pipeline products, strategic alliances and partnerships, and the effects of any recent merger or acquisition activity. A directory of more than five dozen leading players worldwide allows readers to access companies' own web sites for further review.

Information for this report was gathered from a wide variety of published sources; interviews with company representatives were then conducted to assess trends, and form the basis of the forecasting and competitive analysis.

This report is designed for business development and other senior executives, marketers, R&D managers, investors, VCs, consultants, entrepreneurs and others who require an in-depth understanding of the current status of the allergy therapeutics market and potential new products. More than 50 detailed tables or figures provide key data about items such as strategic alliances, M&As, market size, segments and the like.

Content

Executive Summary
1. Overview of the Global Allergy Medications Market
- 1.1 Allergies as a Medical Condition
  - 1.1.1 Types of Allergies
  - 1.1.2 Signs and Symptoms
  - 1.1.3 Physiological Response
  - 1.1.4 Prevalence
- 1.2 Medical Treatment of Allergies
  - 1.2.1 Prescription Medications: Current Usage & Unmet Needs
    - 1.2.1.1 U.S.
    - 1.2.1.2 Europe
    - 1.2.1.3 Japan
    - 1.2.1.4 ROW
  - 1.2.2 Non-Prescription Products: Current Usage & Unmet Needs
    - 1.2.2.1 U.S.
    - 1.2.2.2 Europe
    - 1.2.2.3 Japan
    - 1.2.2.4 ROW
- 2 Global Allergy Medications Market Forecast 2008 - 2013
  - 2.1 Rx Allergy Medications Market
    - 2.1.1 Rx Allergy Drug Market Forecast by Product
      - 2.1.1.1 Growth Drivers
      - 2.1.1.2 Market Restraints
    - 2.1.2 Rx Allergy Drug Market Forecast by Region
    - 2.1.3 Rx Allergy Drug Market Forecast by Product Class
  - 2.2 OTC Allergy Drug Market
    - 2.2.1 OTC Allergy Drug Market Forecast by Product
    - 2.2.2 Growth Drivers
    - 2.2.3 Market Restraints
    - 2.2.4 OTC Allergy Drug Market Forecast by Region
    - 2.2.5 OTC Allergy Drug Market Forecast by Product Class
  - 2.3 Rx & OTC Allergy Drug Market
    - 2.3.1 Rx & OTC Allergy Drug Market Forecast by Leading Manufacturers
    - 2.3.2 Rx & OTC Allergy Drug Market Share of Leading Drug Manufacturers
- 3. Allergy Drug Development: New Molecular Entities
  - 3.1 All Allergy Drug Developers Position
    - 3.1.1 Challenges in Allergy Drug Development
  - 3.2 Key Products Under Development
    - 3.2.1 Antihistamines
      - 3.2.1.1 Physiology and Mechanism of Action
      - 3.2.1.2 Leading Antihistamine Allergy Drug Candidates
    - 3.2.2 Corticosteroids
      - 3.2.2.1 Physiology and Mechanism of Action
      - 3.2.2.2 Leading Corticosteroid Allergy Drug Candidates
    - 3.2.3 Mast Cell Inhibitors
      - 3.2.3.1 Physiology and Mechanism of Action
      - 3.2.3.2 Leading Mast Cell Inhibitor Allergy Drug Candidates
    - 3.2.4 Allergy Immunotherapy
      - 3.2.4.1 Physiology and Mechanism of Action
      - 3.2.4.2 Leading Immunotherapy Allergy Drug Candidates
    - 3.2.5 Vaccines
      - 3.2.5.1 Physiology and Mechanism of Action
      - 3.2.5.2 Leading Allergy Vaccine Candidates
    - 3.2.6 Other Types of Allergy Drugs
      - 3.2.6.1 Physiology and Mechanism of Action
      - 3.2.6.2 Other Leading Allergy Candidates
  - 3.3 Global Market Forecast for New Allergy Drugs, 2008 - 2013
    - 3.3.1 New Allergy Drug Market Forecast: Total and Segment Market
    - 3.3.2 Growth Drivers
      - 3.3.2.1 The Importance of Patents
    - 3.3.3 Market Restraints
- 4. Allergy Drug Development: Indication Expansion
  - 4.1 Indication Expansion for New Usage
    - 4.1.1 The Economic Benefits of Indication Expansion
    - 4.1.2 Challenges in Allergy Drug Indication Expansion
  - 4.2 Key Products Under Development
    - 4.2.1 Database of Allergy Indication Expansion Initiatives by Company
    - 4.2.2 Leading Areas of R&D Activity
      - 4.2.2.1 Clarinex
      - 4.2.2.2 Nasonex
      - 4.2.2.3 Patanase
      - 4.2.2.4 Singulair
      - 4.2.2.5 Veramyst
      - 4.2.2.6 Xolair
      - 4.2.2.7 Xyzal
  - 4.3 Global Market Forecast for Allergy Drug Indication Expansions
    - 4.3.1 Growth Drivers
    - 4.3.2 Market Restraints
- 5. Allergy Drug Development: Basic Research
  - 5.1 Basic Research Group & Activity
    - 5.1.1 Challenges in Basic Allergy Research
  - 5.2 Key Areas of Investigation
  - 5.3 Unanswered Questions
- 6. Strategic Alliances for Allergy Drug Development
  - 6.1 Types of Strategic Alliances
  - 6.2 Current Strategic Alliances for Allergy Drug Development
- 7. Activities of the Leading Allergy Drug Developers
  - 7.1 Alcon Research
  - 7.2 Allergy Therapeutics
  - 7.3 AstraZeneca
  - 7.4 GlaxoSmithKline
  - 7.5 Johnson & Johnson
  - 7.6 Meda AB
  - 7.7 Merck
  - 7.8 Novartis
  - 7.9 Sanofi-Aventis
  - 7.10 Schering-Plough
  - 7.11 Sepracor
  - 7.12 UCB Pharma
- 8. Total Allergy Drug Market: Forecasts & Directions
  - Figure 8-1. Total Allergy Drug Sales Growth by Segment, 2008 - 2013
  - Figure 8-2. Allergy Drug Market Share by Segment, 2008
  - Figure 8-3. Allergy Drug Market Share by Segment, 2013
- 9. Other Top Companies with Allergy Projects
  - Table 9-1. Other Top Companies with Late Stage Allergy Projects
  - Table 9-2. Other Top Companies with Early Stage Allergy Projects
- 10. Database of Allergy Drug Developers